Heart Groups: Clear Risks With HCQ for COVID-19

April 10, 2020 by Mandy Qualls

Filed under COVID-19 for Employers, COVID-19 for the Workforce, For Employers, For the Workforce

Last modified April 11, 2020

AHA/ACC/HRS caution on malaria drug plus antibiotic

A warning to those considering combination therapy with hydroxychloroquine (HCQ) for COVID-19: individually, some medications being considered have been known to put users at risk of sudden cardiac death, major U.S. medical societies said.

https://www.medpagetoday.com/infectiousdisease/covid19/85870?xid=nl_mpt_DHE_2020-04-10&eun=g5524d0r&utm_source=Sailthru&utm_medium=email&utm_campaign=Daily%20Headlines%20Top%20Cat%20HeC%20%202020-04-10&utm_term=NL_Daily_DHE_dual-gmail-definition

Share this

Related Articles

                            Leave a Comment